User profiles for "author:Toni Choueiri"

Toni Choueiri

Dana-Farber Cancer Institute
Verified email at dfci.harvard.edu
Cited by 111158

[HTML][HTML] Post-acute COVID-19 syndrome

A Nalbandian, K Sehgal, A Gupta, MV Madhavan… - Nature medicine, 2021 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen
responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in …

Systemic therapy for metastatic renal-cell carcinoma

TK Choueiri, RJ Motzer - New England Journal of Medicine, 2017 - Mass Medical Soc
Kidney cancers have been extensively studied, and insights from an increased
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …

Targeting the HIF2–VEGF axis in renal cell carcinoma

TK Choueiri, WG Kaelin Jr - Nature medicine, 2020 - nature.com
Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …

[HTML][HTML] Nivolumab versus everolimus in advanced renal-cell carcinoma

RJ Motzer, B Escudier, DF McDermott… - … England Journal of …, 2015 - Mass Medical Soc
Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …

[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma

RJ Motzer, NM Tannir, DF McDermott… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …

[PDF][PDF] The immune landscape of cancer

V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone… - Immunity, 2018 - cell.com
We performed an extensive immunogenomic analysis of more than 10,000 tumors
comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer …

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

NM Kuderer, TK Choueiri, DP Shah, Y Shyr… - The Lancet, 2020 - thelancet.com
Background Data on patients with COVID-19 who have cancer are lacking. Here we
characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify …

[HTML][HTML] Pembrolizumab as second-line therapy for advanced urothelial carcinoma

J Bellmunt, R De Wit, DJ Vaughn… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced urothelial carcinoma that progresses after platinum-
based chemotherapy have a poor prognosis and limited treatment options. Methods In this …

[HTML][HTML] Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma

TK Choueiri, T Powles, M Burotto… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of nivolumab plus cabozantinib as compared with those
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …

[HTML][HTML] Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma

R Motzer, B Alekseev, SY Rha, C Porta… - … England Journal of …, 2021 - Mass Medical Soc
Background Lenvatinib in combination with pembrolizumab or everolimus has activity
against advanced renal cell carcinoma. The efficacy of these regimens as compared with …